Vorinostat and Palliative Radiotherapy
NCT00455351
·
clinicaltrials.gov ↗
PHASE1
Phase
COMPLETED
Status
15
Enrollment
OTHER
Sponsor class
Conditions
Pelvic Cancer
Radiotherapy
Interventions
DRUG:
Vorinostat
Sponsor
Oslo University Hospital